We are live on ! Find out more
DCMIC

Decheng Capital Management III (Cayman) Portfolio holdings

AUM $300M
1-Year Est. Return 15.74%
This Fund
S&P 500
This Quarter Est. Return
+0.4%
1 Year Est. Return
+15.74%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$276M
AUM Growth
+$12.1M
Cap. Flow
+$38.2M
Cap. Flow %
13.86%
Top 10 Hldgs %
78.99%
Holding
28
New
3
Increased
5
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$16.5M
2
APGN
Apexigen, Inc. Common Stock
APGN
+$15.4M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$3.75M
4
ALBO
Albireo Pharma Inc
ALBO
+$2.17M
5
TXG icon
10x Genomics
TXG
+$2.12M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$4.9M
2
MASS icon
908 Devices
MASS
+$412K
3
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
+$76K

Sector Composition

Rank Sector Weight
1 Healthcare 99.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALPN
1
DELISTED
Alpine Immune Sciences Inc
ALPN
$48.3M 17.51%
6,708,288
+2,000,000
+42% +$16.5M
ZNTL icon
2
Zentalis Pharmaceuticals
ZNTL
$302M
$39.5M 14.33%
1,824,583
– –
HLTH
3
DELISTED
Cue Health Inc. Common Stock
HLTH
$27M 9.8%
8,980,909
– –
ILMN icon
4
Illumina
ILMN
$28.4B
$24.8M 9%
133,782
-24,775
-16% -$4.9M
RCUS icon
5
Arcus Biosciences
RCUS
$3.64B
$22.8M 8.25%
869,790
– –
RXDX
6
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$14.8M 5.35%
250,000
– –
ALBO
7
DELISTED
Albireo Pharma Inc
ALBO
$12.1M 4.38%
623,342
+105,000
+20% +$2.17M
TXG icon
8
10x Genomics
TXG
$6.61B
$10.2M 3.71%
359,554
+55,570
+18% +$2.12M
EQ icon
9
Equillium
EQ
$133M
$9.87M 3.58%
4,447,308
– –
PACB icon
10
Pacific Biosciences
PACB
$370M
$8.51M 3.08%
1,463,872
– –
ACET icon
11
Adicet Bio
ACET
$74.7M
$8.25M 2.99%
36,250
– –
WHWK
12
Whitehawk Therapeutics
WHWK
$271M
$7.44M 2.7%
526,329
– –
MRSN
13
DELISTED
Mersana Therapeutics
MRSN
$6.11M 2.22%
36,171
– –
APGN
14
DELISTED
Apexigen, Inc. Common Stock
APGN
$5.12M 1.85%
+1,894,551
New +$15.4M
BYSI icon
15
BeyondSpring
BYSI
$35.8M
$4.91M 1.78%
4,958,143
+1
+0% +$1
HZNP
16
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.88M 1.77%
78,900
+23,500
+42% +$1.64M
TERN
17
DELISTED
Terns Pharmaceuticals
TERN
$4.21M 1.53%
714,285
– –
AURA icon
18
Aura Biosciences
AURA
$826M
$3.81M 1.38%
210,000
– –
SGEN
19
DELISTED
Seagen Inc. Common Stock
SGEN
$3.15M 1.14%
+23,014
New +$3.75M
WGS icon
20
GeneDx Holdings
WGS
$2.3B
$3M 1.09%
103,604
– –
ARGX icon
21
argenx
ARGX
$54.1B
$1.95M 0.71%
+5,529
New +$2.05M
SCYX icon
22
SCYNEXIS
SCYX
$52M
$1.33M 0.48%
69,444
– –
OWLT icon
23
Owlet
OWLT
$160M
$961K 0.35%
64,171
– –
NAUT icon
24
Nautilus Biotechnolgy
NAUT
$115M
$636K 0.23%
300,000
– –
NBSE
25
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$395K 0.14%
50,000
– –
1
2

Similar funds

IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
KBC
Key Bridge Compliance $319M AUM

Decheng Capital Management III (Cayman)'s Q3 2022 Portfolio in Review

As of Q3 2022, Decheng Capital Management III (Cayman) held 28 positions worth $276M, up 4.6% from $264M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Decheng Capital Management III (Cayman) deployed $38.2M of net new capital in Q3 2022, opening 3 new positions and adding to 5 existing holdings. Its largest new stake was Apexigen, Inc. Common Stock: 1,894,551 shares worth $5.12M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Illumina, an estimated $4.9M trimmed.

  • Decheng Capital Management III (Cayman)'s largest Q3 2022 buy was Apexigen, Inc. Common Stock: 1,894,551 shares worth $5.12M.
  • Decheng Capital Management III (Cayman) added most to Alpine Immune Sciences Inc in Q3 2022, an estimated $16.5M increase.
  • Decheng Capital Management III (Cayman)'s biggest Q3 2022 reduction was Illumina, cutting an estimated $4.9M.
  • Decheng Capital Management III (Cayman) fully exited 908 Devices in Q3 2022, selling an estimated $412K.
  • Decheng Capital Management III (Cayman)'s ten largest holdings make up 79% of its $276M portfolio in Q3 2022.
  • Decheng Capital Management III (Cayman) opened 3 new positions and closed 2 in Q3 2022.
  • Decheng Capital Management III (Cayman)'s portfolio value rose 4.6% quarter-over-quarter to $276M.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q3 2022, filed 8 Nov 2022.